

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-103) MAFTIVIMAB

PRONUNCIATION maf tiv' i mab

THERAPEUTIC CLAIM Treatment of Ebola virus disease

CHEMICAL NAME

1. Immunoglobulin G1, anti-(Zaire ebolavirus glycoprotein) (human monoclonal REGN3479 γ 1-chain), disulfide with human monoclonal REGN3479 κ -chain, dimer

2. Immunoglobulin G1-kappa, anti-(*Zaire ebola virus* Envelope glycoprotein); human monoclonal antibody; γ 1 heavy chain (1-448) [human VH (*Homo sapiens* IGHV3-23*04 (96%) –(IGHD)-IGHJ3*02 (93%)) [8.8.11]] (1-118) -*Homo sapiens* IGHG1*01 (119-448) (221-213')-disulfide with κ light chain (1'-213') [human V-KAPPA (*Homo sapiens* IGKV1-39*01 (99%) – IGKJ5*01 (92%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')], dimer (227-227":230-230")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

| | | | | | |
|------------|------------|------------|------------|------------|-----|
| EVQLVESGGG | LVQPFGSLRL | SCAASGFTSS | SYAMNWRQA | PGKLEWVST | 50 |
| ISGMGGSTYY | ADSVKGRFTI | SRDNSKNTLY | LQMNSLRAED | TAVYYCAKRG | 100 |
| YPHSFDIWGQ | GTMVTVSSAS | TKGPSVFPLA | PSSKSTSGGT | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YSLSSVVTVP | SSSLGTQTYI | 200 |
| CNVNHKPSNT | KVDKKVEPKS | CDKTHTCPCC | PAPELLGGPS | VFLFPPKPKD | 250 |
| TLMISRTPEV | TCVVDVDSHE | DPEVKFNWYV | DGVEVHNAKT | KPREEQYNST | 300 |
| YRVVSVLTVL | HQDWLNGKEY | KCKVSNKALP | APIEKTISKA | KGQPREPQVY | 350 |
| TLPPSRDEL | KNQVSLTCLV | KGFYPDIAV | EWESNGQPEN | NYKTTTPVLD | 400 |
| SDGSFFLYSK | LTVDKSRWQQ | GNVFSQVMH | EALHNHYTQK | SLSLSPGK | 448 |

Light chain

| | | | | | |
|------------|------------|-------------|------------|------------|------|
| DIQMTQSPSS | LSASVGRVTV | ITCRASQSSIS | SFLNWyQQKP | GKAPKLLIYA | 50' |
| ASSLQSGVPS | RFSGSGSGTD | FTLTISSLQP | EDFATYYCQQ | SYSTLTFGQG | 100' |
| TRLEIKRTVA | APSVFIFFPS | DEQLKSGTAS | VVCLLNNFYP | REAKVQWKVD | 150' |
| NALQSGNSQE | SVTEQDSKDS | TYSLSSTLTL | SKADYEKHKV | YACEVTHQGL | 200' |
| SSPVTKSFNR | GEC | | | | 213' |

Disulfide bridges

| | | | | | | | |
|----------|-----------|----------|----------|-----------|-----------|---------|-----------|
| 22-96 | 22"-96" | 23'-88' | 23"-88" | 133'-193' | 133"-193" | 145-201 | 145"-201" |
| 213'-221 | 213"-221" | 227-227" | 230-230" | 262-322 | 262"-322" | 368-426 | 368"-426" |

Glycosylation sites (N)

Asn-298 Asn-298"

MOLECULAR FORMULA $C_{6368}H_{9886}N_{1706}O_{2008}S_{46}$ (peptide only)

MOLECULAR WEIGHT 143.9 kDa (peptide only)

TRADEMARK None as yet

| | |
|----------------------------|---------------------------|
| SPONSOR | Regeneron Pharmaceuticals |
| CODE DESIGNATIONS | REGN3479 |
| <u>CAS</u> REGISTRY NUMBER | 2135632-36-7 |
| UNII | KOP95331M4 |
| WHO NUMBER | 11034 |

gbk